-
Mashup Score: 9
Latest topline data from the Phase 3 MARIPOSA study shows amivantamab plus lazertinib is the first regimen to demonstrate superior overall survival benefit compared to the current standard of care osimertinib1 Median overall survival improvement is expected to exceed one year1
Source: www.jnj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29
Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer
Source: www.jnj.comCategories: General Medicine News, Hem/OncsTweet-
Proud to share a topline overall survival announcement from the Phase 3 MARIPOSA trial in EGFR-mutated #NSCLC. These data reinforce @JNJInnovMed’s dedication to help transform what’s possible in cancer care and potentially give patients more time and hope: https://t.co/Ug1aHpoqJP https://t.co/jrKUaLTurl
-
-
Mashup Score: 29
Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer
Source: www.jnj.comCategories: General Medicine News, Hem/OncsTweet-
Proud to share a topline overall survival announcement from the Phase 3 MARIPOSA trial in EGFR-mutated #NSCLC. These data reinforce @JNJInnovMed’s dedication to help transform what’s possible in cancer care and potentially give patients more time and hope: https://t.co/Ug1aHpoqJP https://t.co/jrKUaLTurl
-
-
Mashup Score: 29
Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer
Source: www.jnj.comCategories: General Medicine News, Hem/OncsTweet-
Proud to share a topline overall survival announcement from the Phase 3 MARIPOSA trial in EGFR-mutated #NSCLC. These data reinforce @JNJInnovMed’s dedication to help transform what’s possible in cancer care and potentially give patients more time and hope: https://t.co/Ug1aHpoqJP https://t.co/jrKUaLTurl
-
-
Mashup Score: 32
Sorry, I don’ t understand. Please try again This multitargeted, chemotherapy-free combination demonstrated superiority over osimertinib monotherapy for the first-line treatment of patients with EGFR-mutated NSCLC In the Phase 3 MARIPOSA study, amivantamab plus lazertinib significantly reduced the risk of disease progression or death by 30 percent versus osimertinib monotherapy 1 BEERSE, BELGIUM (30 December 2024) – Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the
Source: innovativemedicine.jnj.comCategories: General Medicine News, Hem/OncsTweet-
Excited to announce the European Commission approved our chemotherapy-free combination therapy for the first-line treatment of EGFRm #NSCLC. Proud to be part of a team at #JNJOncology that continues to drive innovation for patients. https://t.co/5tpp9hepug https://t.co/j2UKERe21E
-
-
Mashup Score: 3
The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients with advanced NSCLC with EGFR ex19del or L858R substitution mutations1 In the Phase 3 MARIPOSA study, amivantamab plus lazertinib significantly reduced risk of disease progression or death by 30 percent versus osimertinib monotherapy1
Source: www.jnj.comCategories: General Medicine News, Hem/OncsTweet-
Exciting progress for patients in Europe! A CHMP positive opinion brings us closer to offering the first chemotherapy-free combination therapy for first-line treatment of EGFRm #NSCLC. Proud to be part of the journey to redefine standards of care. https://t.co/yZ9E4mtNdi https://t.co/8U4CGxP7mw
-
-
Mashup Score: 17Oncology - 4 month(s) ago
We work daily to get in front of cancer, convening the brightest minds to create and deliver new ways to detect, intercept and one day cure this disease.
Source: www.jnj.comCategories: General Medicine News, Hem/OncsTweet-
Getting #InFrontofCancer means recognizing the current standard of care is not enough for our patients – they deserve more. This #LungCancerAwarenessMonth, I’m honored to share what drives my passion to get in front of this disease: https://t.co/negWcJdFW1 https://t.co/IO2KmZGMhK
-
-
Mashup Score: 20
/PRNewswire/ — Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) in…
Source: www.prnewswire.comCategories: General Medicine News, Hem/OncsTweet-
The U.S. FDA approved our targeted therapy in combination with chemotherapy for patients with previously treated #NSCLC with specific EGFR mutations. This milestone marks @JNJInnovMed’s third new indication in six months for this targeted therapy: https://t.co/idwHB2Vxdn https://t.co/TddzWhCEJH
-
-
Mashup Score: 9A transformative approach to lung cancer treatment: Multi-targeted, chemo-free regimens - 6 month(s) ago
Early detection may be the cornerstone of cancer care, but in lung cancer it’s seldom the reality. Just 28% of lung cancers are found in early stages,
Source: www.statnews.comCategories: General Medicine News, Hem/OncsTweet-
Tomorrow kicks off #WCLC24, where my colleagues at @JNJInnovMed will share significant advancements from our #LungCancer portfolio. Learn about our work as we continue to explore new possibilities to improve treatment options for patients:https://t.co/t8t2MvHlSF https://t.co/zkbNGIts2D
-
-
Mashup Score: 46
/PRNewswire/ — Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved RYBREVANT® (amivantamab-vmjw) plus…
Source: www.prnewswire.comCategories: General Medicine News, Hem/OncsTweet-
I’m proud to share the U.S. FDA approved our chemotherapy-free combination regimen for locally advanced or metastatic EGFR-mutated #NSCLC following priority review. This is a remarkable milestone for @JNJInnovMed and everyone affected by this disease: https://t.co/2qsLnLt5YV https://t.co/LQXLpjeMXW
-
Today, we’re one step closer to transforming care for EGFRm #NSCLC. I’m excited to share that the European Commission has now fully approved our chemo-free regimen—a breakthrough that offers a new way forward for patients and their families across the EU: https://t.co/MKWoZbODzj https://t.co/8rcmu90Gdr